Clinical Trials Logo

Adverse Reaction to Drug clinical trials

View clinical trials related to Adverse Reaction to Drug.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05645302 Recruiting - Clinical trials for Adverse Reaction to Drug

Intensive Monitoring Scheme of Lidocaine Cataplasms

Start date: April 6, 2022
Phase:
Study type: Observational

In this center, retrospective research methods are used to collect data. Patients who had used Lidocaine Cataplasms at least once were included consecutively. Taking the time when the patient first used Lidocaine Cataplasms as the starting time (the study baseline), collect the demographic characteristics of the patient, the medication scheme of Lidocaine Cataplasms and other information, as well as the medication safety and other information from the first medication to the end of medication or discharge (whichever occurs first).

NCT ID: NCT04655794 Recruiting - Clinical trials for Adverse Reaction to Drug

Clinical Analysis of Safety in Latent Tuberculosis Infection Prophylaxis Treatment

Start date: April 19, 2018
Phase:
Study type: Observational

The treatment of latent TB with 3HP is an important issue for the prevention of active TB. However, significant proportion of subjects receiving 3HP had adverse reaction. The main purpose of this observation study is to identify subjects who have higher risk to develop adverse reaction. Clinical characteristics and biomarker will be used to predict adverse reaction.

NCT ID: NCT02520570 Recruiting - Clinical trials for Adverse Reaction to Drug

Post-market Safety Reassessment of Ulinastatin for Injection

Start date: August 2014
Phase:
Study type: Observational

1. Investigate the application of ulinastatin(UTI) in real practice clinic.(eg:population character, usage and dosage, course of treatment,etc ) 2. Analysis the incidence of adverse drug reactions /adverse events of ulinastatin, collect the main clinical manifestations, treatment, outcome, influence factors; provide evidence for improving the recommended medication plan of ulinastatin. 3. Evaluate the safety of ulinastatin , obtain scientific conclusion , and provide evidence for appropriate medication to administration department of health authority.

NCT ID: NCT02353455 Recruiting - Clinical trials for Adverse Reaction to Drug

Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity

Start date: March 2013
Phase:
Study type: Observational

Drug metabolism in the liver is subject to large fluctuations (differences between women and men, people of different ethnic backgrounds, children and adults). These large differences are responsible for very different drug effects and side-effects (and especially liver damage caused by drugs) between individuals. Recent scientific findings suggest that blood derived cells can be used to model individual effects of drugs on the liver reflect inter-individual differences. Since liver damage caused by drugs is a diagnosis of exclusion, the aforementioned cells can be used to identify patients that show higher sensitivity to hepatotoxic side-effects and - in case several drugs are involved - identify the causal agent or possible interactions.

NCT ID: NCT01354197 Recruiting - Critical Illness Clinical Trials

The Thai Surgical Intensive Care Study (Thai-SICU Study)

THAI-SICU
Start date: April 2011
Phase: N/A
Study type: Observational

- Overall treatment outcomes of University base SICU - Incidence of adverse events in SICU - Factor associated to adverse events in SICU

NCT ID: NCT00817375 Recruiting - Depression Clinical Trials

Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients

Start date: February 2003
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether pharmacogenomic study predict antidepressant responsiveness in advance before the appearance of the drug effects until 4~6 weeks after drug administration.